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ABSTRACT
Background: Membrane-bound heparan sulphate pro-
teoglycans (HSPGs) act as co-receptors and presenters of
cytokines and are involved in cell–matrix and cell–cell
adhesion.
Aim: To investigate which HSPGs are expressed in knee
joint synovia from patients with different forms of arthritis
and normal individuals.
Methods: Synovial samples were obtained from patients
with early rheumatoid arthritis (n=8), longstanding
rheumatoid arthritis (n=13), psoriatic arthritis (n=7),
osteoarthritis (n=6) and normal joints (n=12).
Expression of syndecan-1, -2, -3 and -4 and glypican-1, -3
and -4 was analysed by immunohistochemistry and dual
label immunofluorescence.
Results: The expression of HSPGs in chronically inflamed
synovium exhibited a differential distribution. Syndecan-1
was present in the mononuclear infiltrates of synovia from
patients with rheumatoid and psoriatic arthritis where it
was expressed by plasma cells. Syndecan-2 was present
mainly in blood vessels where it occurred on endothelial
cells, pericytes and smooth muscle cells. Syndecan-3
stained intensely in endothelial cells but also occurred in
sublining macrophages and the lining layer. Glypican-4
occurred in the lining layer and blood vessels. Increased
expression of these HSPGs was apparent in rheumatoid
and psoriatic compared to osteoarthritic and normal
synovia. Little or no staining for syndecan-4, glypican-1
and glypican-3 was seen in all samples.
Discussion: Selected HSPGs, such as syndecan-1, -2
and -3 and glypican-4, could play a part in the
pathophysiology of arthritis, such as the migration and
retention of leukocytes and angiogenesis in the chronically
inflamed synovium.
Proteoglycans are composed of glycosaminoglycan
(GAG) chains, such as heparan sulphate, chondroi-
tin sulphate, keratan sulphate or dermatan sul-
phate, covalently attached to a core protein. Two
major classes of proteoglycans contain heparan
sulphate chains: syndecans, which have a trans-
membrane domain in their core proteins, and
glypicans, which are attached to the cell membrane
by glycosylphosphatidylinositol (GPI)-anchors.
12
In the basement membrane perlecan is the major
component that bears heparan sulphate.
To date, four syndecans and six glypicans have
been identified. Syndecans are the major source of
cell surface heparan sulphate. They are expressed in
a cell-, tissue- and development-specific manner.
1
Syndecan-1 and -4 have been shown in endothelial
cells,
3 however, syndecan-1 is mainly expressed on
epithelial cells with syndecan-4 expression on
many cell types. Changes in their expression occur
during embryogenesis, wound healing and carcino-
genesis.
4–6 Although syndecan-2 has been identified
as an endothelial heparan sulphate proteoglycan
(HSPG),
7 expression within tissues has also been
shown on fibroblasts, for example, in skin and
periodontium,
8 with expression also occurring on
carcinoma cells.
9 Syndecan-3 was first identified on
neuronal cells and has been associated with the
generation of cerebellar fibrillar plaques in
Alzheimer disease.
10 It is also an HSPG of the
musculoskeletal system.
11–14 Glypicans are widely
expressed in embryonic and adult tissues such as
ovary, intestine and central nervous system, and
are involved in growth factor signalling.
15 They
play a role in tissue growth, regeneration and
cancer.
Rheumatoid arthritis (RA) is characterised by
chronic inflammation of the synovium of the
joints, resulting in stiffness, pain and—as the
disease progresses—erosion of the joint tissues
and deformities.
16 Psoriatic arthritis (PsA) resem-
bles RA in being an inflammatory disease leading
to joint destruction, but differs from RA in several
ways including the distribution of affected joints,
the presence of skin lesions and enthesopathy, and
the absence of rheumatoid factor, characteristic
rheumatoid erosions and periarticular osteopoenia
on radiographs. The exact pathogenesis of RA and
PsA is largely unknown, but it is clear that a
number of factors may be involved either indivi-
dually or in combination. During RA, characteristic
histopathological changes occur; the synovial lin-
ing layer undergoes thickening and hypertrophy,
and in the sublining leukocytes such as monocytes,
T cells and B cells migrate into the tissue where
they accumulate.
17
There is increasing evidence that HSPGs are
involved in inflammation.
18 Using animal knock-
out models and isolated cells, syndecan-1 and
syndecan-4 have been shown to be involved in
regulating inflammatory responses,
19 binding che-
mokines
20 21 and forming chemokine gradients.
22 23
The chemokine CXCL8 has been shown to bind to
syndecan-2 in cultured human umbilical vein
endothelial cells
24 and we recently showed the
induction of a CXCL8 binding site on syndecan-3
in the endothelial cells of the RA synovium.
14
However, little is known about the expression of
syndecans and glypicans by the various cell types
of the chronically inflamed synovium, although
other proteoglycans bearing GAGs such as derma-
tan sulphate have been identified in this tissue.
25
HSPGs are of interest as they are co-receptors
for cytokines (eg, fibroblast growth factor), pre-
senters of chemokines and are involved in
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26–30 Hence they are
likely candidates involved in several pathomechanisms in
chronically inflamed synovia, such as angiogenesis and the
migration and retention of leukocytes. Therefore, this study
aimed to compare the expression patterns of syndecan-1, -2, -3,
and -4, and glypican-1, -3 and -4 in the RA, PsA and normal
synovium.
MATERIALS AND METHODS
Tissue samples
All samples of synovia were obtained, with informed consent,
from the suprapatellar pouch and medial gutter from knee
joints. Clinical and demographic details are given in table 1. For
early RA, synovia were taken by arthroscopic needle biopsy
from patients diagnosed with RA according to the American
Table 1 Clinical and demographic details of patients
Patient Gender Age Diagnosis Duration (years) ESR RF (titre) Histology score Medication
1 M 52 Normal (meniscal tear) 1.2 ND ND 0 None
2 F 53 Normal (articular cartilage
degeneration)
0.25 ND ND 1 None
3 M 57 Normal (articular cartilage
degeneration)
1 ND ND 0 None
4 F 57 Normal (meniscal tear) 1.5 ND ND 0 None
5 M 58 Normal (meniscal tear and cartilage
degeneration)
0.5 ND ND 0 None
6 F 41 Normal (articular cartilage
degeneration)
0.5 ND ND 0 None
7 M 38 Normal (articular cartilage damage) 1 ND ND 0 None
8 F 55 Normal (meniscal and articular
cartilage damage)
2 ND Negative 0 None
9 F 29 Normal (articular cartilage
degeneration)
11 ,10 Negative 0 None
10 M 28 Normal (meniscal tear) 1 ND ND 0 None
11 M 44 Normal (meniscal tear) 15 ND ND 0 NSAID
12 M 55 Normal (articular cartilage damage) .1 ND ND 0 None
1 ND ND ERA 1.5 14 Positive (640) 3 NSAID
2 ND ND ERA 0.25 23 Positive (80) 1 NSAID
3 ND ND ERA 0.6 ND ND 1 ND
4 ND ND ERA 0.25 51 Positive (640) 2 NSAID
5 ND ND ERA 0.5 44 Positive (640) 2 None
6 ND ND ERA 0.3 34 Positive (170) 1 None
7 ND ND ERA 1 48 Positive (160) 2 None
8 ND ND ERA 0.1 12 Positive (640) 3 NSAID
1 F 48 RA 18 24 Positive (400) 3 MTX, NSAID
2 F 47 RA 15 18 Negative 1 St, NSAID, analgesic
3 F 62 RA 26 64 Positive (.1280) 2 Sulphasalazine, NSAID
4 F 45 RA 20 71 Positive (640) 3 Sulphasalazine, azathioprine,
NSAID
5 M 73 RA 15 59 Positive(1280) 2 D-Penicillamine, NSAID,
analgesic
6 F 43 RA 5 23 Positive (640) 2 MTX
7 F 52 RA 20 30 Positive (1280) 3 MTX, Hydroxychloroquine,
NSAID, st, gold
8 F 67 RA 7 105 Positive (160) 3 Steroid, NSAID
9 F 63 RA 8 100 Positive (320) 3 MTX, st, analgesic
10 F 62 RA 38 100 Positive (640) 3 MTX, st
11 F 55 RA 21 68 Positive (1280) 2 NSAID
13 F 68 RA 28 70 Positive (800) 2 Analgesic
1 M 42 OA 2 ND Negative 1 None
2 F 61 OA .4 ND ND 2 Analgesic
3 F 72 OA .5 ND ND 1 NSAID, analgesic
4 F 33 OA 20 ND Negative 1 NSAID
5 M 78 OA 15 ND ND 1 NSAID
6 F 83 OA 13 ND ND 2 NSAID
1 M 22 PsA 8 11 Negative 1 Aulin
2 F 40 PsA ,1 28 Negative 2 NSAID, st, tar pomeda,
reductil
3 F 60 PsA 13 4 Negative 2 Betnovate, Lipitor
4 F 50 PsA ,1 5 Negative 0 DMARD
5 M 35 PsA 2 11 Negative 2 NSAID, Losec, analgesic
6 F 55 PsA 28 10 Negative 3 St, MTX
7 F 27 PsA 20 24 Negative 3 NSAID, st
DMARD, disease-modifying antirheumatic drug; ERA, early rheumatoid arthritis; MTX, methotrexate; ND, not determined; NSAID, non-steroidal anti-inflammatory drug; OA,
osteoarthritis; PsA, psoriatic arthritis; RA longstanding rheumatoid arthritis; RF, rheumatoid factor; St, steroid.
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disease duration of ,12 months. RA synovia were also taken
at total knee replacement or synovectomies from patients who
fulfilled the ACR criteria and had a disease duration .5y e a r s .
S y n o v i aw e r eo b t a i n e db ya r t h r o s c o p i cb i o p s yo fk n e e so f
patients with PsA. Osteoarthritic (OA) synovia were obtained
at total knee replacement operations. Non-RA synovia, which
were histologically normal, were taken arthroscopically from
patients who had knee joint symptoms for suspected joint
damage. Tissue was frozen in liquid nitrogen-cooled isopen-
tane and stored in the vapour phase of liquid nitrogen. Normal
human skin samples were kindly provided by Dr E Johnston
and Dr C Mangham, Department of Pathology, University of
Birmingham, UK.
Antibodies
The antibodies used were: anti-syndecan-1 (clone B-B4; Serotec,
Oxford, UK); anti-syndecan-2 (mouse IgG1, clone 10H4), anti-
syndecan-3 (mouse IgG1 clone 1C7), anti-syndecan-4 (mouse
IgG1 clone 8G3), anti-glypican-1 (mouse IgG1 clone S1) (all
prepared and supplied by Dr G David, University of Leuven,
Belgium), anti-glypican-3 (Santa Cruz Biotechnologies, Santa
Cruz, California, USA), anti-glypican-4 (rabbit polyclonal anti-
body kindly donated by Professor HD Haubeck, Germany), anti-
human IgG (rabbit polyclonal, Dako code A 0423; Dako,
Glostrup, Denmark), anti-CD20 (Dako clone L26), anti-CD68
(rabbit polyclonal; Santa Cruz Biotech, code sc-9139). The
antibodies to the syndecans and glypicans have already been
shown to be specific using biochemical approaches (eg, western
blotting) and specific staining has been obtained for other
human tissues.
31–37
Immunohistochemistry
The method of Roskams et al
38 was followed, using the anti-
syndecan and anti-glypican-1 antibodies, with minor modifica-
tions; for glypican-3 the method of Patterson et al
14 for
polyclonal antibodies was used with minor modifications, for
glypican-4 the polyclonal antibody was diluted in 10% human
serum and detected with swine anti-rabbit horse radish
peroxidase conjugate diluted in 10% human serum. Briefly,
10 mm thick serial cryostat sections of synovia and skin were
dried for 1 h and stored at 280uC until required. Prior to
immunohistochemical analysis, slides were left to equilibrate to
room temperature for 30 min, fixed in acetone (4uC) for 10 min,
air dried, and then sections were rehydrated in phosphate
buffered saline (PBS) for 5 min. All primary antibodies were
used at 5 mg/ml since initial experiments showed that this
concentration gave the optimum specific staining over the range
2.5–10 mg/ml. Antibody binding was detected using DAB
staining kit (Vector Labs, Burlingame, California, USA).
Sections were counterstained with Mayer Haematoxylin and
mounted. In control experiments isotype matched control
mouse Ig or rabbit Ig were added instead of primary antibodies,
and stained with the DAB kit as above.
Figure 1 Expression of syndecan-1 in
synovia. Sections of human knee
synovium were incubated with an
antibody to syndecan-1 and processed
using immunoperoxidase and
diaminobenzidine (brown). Staining is
present in the mononuclear infiltrates of
patients with early rheumatoid arthritis
(A), longstanding rheumatoid arthritis (B)
and psoriatic arthritis (C). (D) is a
negative control section from the same
individual as (B) except the primary
antibody was replaced by isotype-
matched control IgG1. Original
magnification A 6250, B and D 660,
C 6120.
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For co-localisation of syndecan-1 and IgG, sections were treated
with anti-syndecan-1 and anti-IgG (both at 5 mg/ml) added
together, washed in PBS and incubated with goat anti-mouse
IgG1–fluorescein isothiocyanate (FITC) (1:500 Southern Biotech
code 1070-02; Southern Biotech, Birmingham, Alabama, USA)
and swine anti-rabbit Ig-biotinylated (1:500 Dako code E0353)
containing 10% human serum. The detection of the biotinylated
secondary antibody was by using streptavidin-Alexa 594 (1:1000
Molecular Probes code S-11227; Molecular Probes, Eugene,
Oregon, USA). For co-localisation of syndecan-1 and CD20,
sections were treated with anti-syndecan-1 (5 mg/ml) and anti-
CD20 (2 mg/ml), washed in PBS and incubated with goat anti-
mouse IgG1–FITC (as above) and goat anti-mouse IgG2b-Texas
red(1:100SouthernBiotechcode1090-07)containing10%human
serum. For co-localisation of syndecan-3 and CD68, sections were
incubated with anti-syndecan-3 (5 mg/ml) and anti-CD68 (4 mg/
ml), washed in PBS and treated with goat anti-mouse IgG-Alexa
488 (1:500 Molecular Probes code A11001) and goat anti-rabbit-
Texas red (1:100 Santa Cruz Biotechnology code sc-2780)
containing 10% human serum. All sections were washed in PBS,
rinsed with water, air dried and mounted. In control experiments,
isotype-matched control mouse, goat or rabbit Ig were added
instead of primary antibodies, and treated with relevant
secondary antibodies as above.
Analysis
The immunoreactivity of HSPG expression was scored blind by
two individuals using the following scoring system that
consisted of a combination of staining intensity and number
of positive cells: no staining (–), weak (+), strong (++) and very
strong (+++) (table 2). A histological scoring system was used to
assess the degree of synovial inflammation:
14 0 for normal
intimal layer and no leukocyte infiltration; 1 for small foci/areas
of leukocyte infiltration with two or more synovial lining cells;
2 for synovitis with moderate infiltrations and three or more
synovial lining cells; 3 for severe synovitis with widespread
infiltration and four or more synovial lining cells (table 1).
RESULTS
Cryosections of RA, PsA, OA and non-RA synovia, and normal
skin were incubated with antibodies to each of syndecans-1 to -
4, glypicans-1, –3, and -4 and perlecan.
Figure 2 Co-localisation of syndecan-1
with IgG. Sections of synovia from
longstanding rheumatoid arthritis were
treated with antibodies to syndecan-1 and
human IgG and observed by double label
immunofluorescence microscopy.
Syndecan-1 positive cells (A) co-localise
with IgG (B). Lack of co-distribution of
syndecan-1 (C) and CD20 (D). Original
magnification 6100 (A-D).
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was seen in the lymphocytic infiltrates of patients with long-
standing RA and PsA (fig 1, table 2). Staining was also present in
these infiltrates in early RA (fig 1A), but was weak in OA and
absent in normal synovia. Using double label immunofluores-
cence staining, these syndecan-1 positive cells co-localised with
IgG suggesting that they were plasma cells (fig 2A,B) and their
histological appearance was that of plasma cells. Syndecan-1 and
IgG immunoreactivity were negative in normal synovia. The
syndecan-1 positive cells did not co-localise with CD20 indicating
that they were not immature or mature B cells (fig 2C,D).
Syndecan-2 showed a different distribution compared to
syndecan-1. It occurred mainly within the walls of blood vessels
(fig 3A) in all samples with strong staining in RA, OA and PsA
and weak staining in normal synovia (table 2). The endothelial
cells, pericytes and smooth muscle cells were positive. Some
additional staining was present in the lining layer of early RA
and PsA samples.
Syndecan-3 also localised to blood vessels where it showed a
more selective distribution than syndecan-2; intense labelling
occurred on endothelial cells but pericytes and smooth muscle
cells were negative (fig 3B, table 2). Staining was stronger in the
endothelial cells of chronically inflamed synovia from RA and
PsA, compared to OA and normal. This is in agreement with our
earlier study showing more intense staining of this HSPG in
synovial endothelial cells of longstanding RA compared to
normal.
14 Cells within the sublining connective tissue were
positive for syndecan-3. These cells were macrophages, as
judged by their morphology, and this was confirmed by double
label experiments that showed syndecan-3 co-localising with
CD68 positive cells in RA and normal synovia (fig 3D,E). CD68
negative cells were also positive for syndecan-3 in the sublining.
These cells were identified as being fibroblasts, based on their
morphology, whereas lymphocytic infiltrates were negative.
The lining layer stained strongly for syndecan-3 in RA and PsA
and weakly in OA and normal (fig 3C, table 2).
In synovia from all patients groups, glypican-4 staining
occurred in the blood vessel wall, localising to the endothelium,
pericytes and smooth muscle cells (fig 4, table 2). In addition,
glypican-4 was demonstrated in the lining layer where strong
staining was found in early RA, longstanding RA and PsA. The
staining pattern of perlecan was localised to the lining layer, and
in the sublining positivity was found in the walls of blood
vessels (data not shown). This staining pattern was present in
the synovia from all patient groups and is in agreement with a
previous study of OA synovium.
39
Figure 3 Expression of syndecan-2 and
syndecan-3 in synovia. A.
Immunohistochemistry showing staining
of syndecan-2 in the walls of blood
vessels in the sublining and in the lining
layer of rheumatoid arthrtitis (RA)
synovium. B. Syndecan-3 staining within
endothelial cells and the lining layer in
early RA. C. Detail of syndecan-3 staining
of the lining layer in longstanding RA. D,E.
Double label immunofluorescence
microscopy with syndecan-3 (D) and
CD68 (E) antibodies showing syndecan-3
localising to sublining macrophages in
RA. Original magnification 6100 (A),
6200 (B) 6300 (C-E).
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(fig 5A) apart from some weak staining in the lining layer of early
RAandPsA(table2).Synovialstainingforglypican-1andglypican-
3 was negative (fig 5C,E). However, expression of syndecan-4,
glypican-1andglypican-3wasdetectedintheepidermis(fig5B,D,F)
and blood vessels of human skin, similar to that previously
reported,
8 providing a positive control for these antibodies.
Immunostaining was negative in all experiments in which the
primary antibodies to HSPGs were replaced with the same
concentrations of control mouse (fig 1D), goat or rabbit Ig.
DISCUSSION
The results of the present study show that the HSPGs expressed
in chronically inflamed synovium show a differential expression
pattern. Syndecan-1 was present in the mononuclear infiltrates
of synovia from patients with RA and PsA where it occurred in
plasma cells. This HSPG has been used as a marker of epithelial
cells and plasma cells.
40–44 In the present study it was a selective
marker for the latter cell type, which is in agreement with other
studies that used syndecan-1 to identify these cells in
chronically inflamed synovia.
43 44
Syndecan-2 was present mainly in blood vessels where it
occurred in endothelial cells, pericytes and smooth muscle cells.
Expression of syndecan-2 has been shown in mesenchymal,
neuronal and cancer cells.
45 46 In line with our results this HSPG
has also been found in endothelial cells, for example in the brain
where it is highly expressed.
47 There is evidence that syndecan-2
is involved in angiogenesis that may be related to the interaction
Table 2 Cellular distribution of heparan sulphate proteoglycans in normal (n=12), early rheumatoid (n=8), longstanding rheumatoid (n=13),
osteoarthritis (n=6) and psoriatic (n=7) synovium
Tissue Syndecan-1 Syndecan-2 Syndecan-3 Syndecan-4 Glypican-1 Glypican-3 Glypican-4
Normal
Lining layer 22+ 222+
Sublining:
Fibroblasts 22+ 2222
Mononuclear infiltrates 2222222
Macrophages 22+ 2222
Endothelium 2 ++222+
Smooth muscle cells 2 + 2222+
Pericytes 2 + 2222+
Early rheumatoid ND
Lining layer 2 ++ + +2 ++
Sublining:
Fibroblasts 22+ 22 2
Mononuclear infiltrates ++ + 222 2
Macrophages 22++ 22 2
Endothelium 2 ++ +++ 22 +
Smooth muscle cells 2 ++ 222 +
Pericytes 2 + 222 +
Longstanding rheumatoid
Lining layer 22++ 222++
Sublining:
Fibroblasts 22+ 2222
Mononuclear infiltrates +++ + 22222
Macrophages 22++ 2222
Endothelium 2 ++ +++ 222+
Smooth muscle cells 2 ++ 2222+
Pericytes 2 ++ 2222+
Osteoarthritis
Lining layer 22+ 222+
Sublining:
Fibroblasts 22+ 2222
Mononuclear infiltrates + 222222
Macrophages 22++ 2222
Endothelium 2 ++ ++ 222+
Smooth muscle cells 2 ++ 2222+
Pericytes 2 + 2222+
Psoriatic
Lining layer 2 ++ + +22++
Sublining:
Fibroblasts 22+ 2222
Mononuclear infiltrates +++ + 22222
Macrophages 22++ 2222
Endothelium 2 ++ +++ 222+
Smooth muscle cells 2 ++ 22- 2 +
Pericytes 2 ++ 2222+
Immunoreactivity of cells: 2 no staining; + weak staining; ++ strong staining; +++ very strong staining.
ND, not determined.
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48 This is
of particular interest since in the RA synovium angiogenesis is a
significant pathological event responsible for its enlargement
and invasive properties, and suggests an involvement of
syndecan-2 in these mechanisms.
Syndecan-3 was abundantly expressed in the endothelial cells
of chronically inflamed synovia. This pattern resembled that of
syndecan-2 but differed in being undetectable in the pericytes or
smooth muscle cells of blood vessels. There has been a previous
report of the expression of syndecan-3 by human endothelial
cells. This has been shown in normal liver and intense reactivity
occurs on endothelial cells in heptacellular carcinomas.
38 49 In
addition, syndecan-3 has recently been shown in the blood
vessels of non-malignant ovarian tissues with intense reactivity
occurring on blood vessels in ovarian cancer.
50 In the RA
synovium, out of the syndecans and glypicans tested, syndecan-
3 was the most abundantly detected HSPG in endothelial cells.
Endothelial syndecan-3 selectively binds the chemokine CXCL8,
suggesting a role in leukocyte trafficking into the synovium,
whereas syndecan-2 and glypican-4 do not appear to bind this
chemokine despite the presence of these HSPGs in the synovial
endothelium.
14 A role for syndecan-3 in leukocyte extravasation
is further suggested since heparan sulphate can act as an
adhesion molecule involved in blood leukocyte-endothelial
interactions.
51 In the current study syndecan-3 was not purely
a marker of endothelial cells since it also localised to CD68+
macrophages in the sublining. In addition, the lining layer was
positive for syndecan-3 suggesting that macrophages may also
be positive in this layer, since macrophages are known to be a
major component of the lining layer.
17 In this connection
macrophages have been shown to express syndecan-3 in rat
liver
52 and human liver with chronic cholestatic disease.
49
Syndecan-3 is also expressed by chondrocytes in normal and
OA articular cartilage where it is a regulator of chondrocyte
proliferation.
12 53 Therefore, taken with our findings in the
synovium, syndecan-3 appears to be an HSPG particularly
associated with joint tissues.
Glypican-4 showed a similar distribution to that of syndecan-
2, localising to endothelial cells, pericytes and smooth muscle
cells in the walls of blood vessels. In addition, this HSPG
occurred in the lining layer. By contrast, glypican-1 and
glypican-3 were not detectable indicating that there is
specificity in glypican expression in the synovium. Using the
same antibody as ours, glypican-4 has been shown to be
expressed in human kidney and bone marrow stromal and
haematopoietic cells;
37 54 it is also expressed in development and
binds fibroblast growth factor-2.
55 56
Several differences in HSPG expression were noted between
inflamed and normal synovia. Syndecan-1 was abundantly
expressed in RA and PsA samples whereas it was absent in
normal and weakly expressed in OA. The lack of syndecan-1 in
normal synovia relates to the absence of plasma cells in these
samples whereas in RA and PsA these cells were abundantly
present.Normalsynoviawere taken from patients withsuspected
meniscal damage of the knee and were essentially non-inflamed.
The lack of lymphocytes of the B lineage is in agreement with a
recent study by Singh et al
57 who could not demonstrate L26+ B
lymphocytes in normal knee synovia whereas CD3+,C D 4 + and
CD8+ T lymphocytes could be detected. Other changes in our
study included an increased staining of syndecan-3 in endothelial
cells, sublining macrophages and lining layer cells of RA and PsA
in comparison to normal. Syndecan-2 staining was more intense
in the blood vessels of RA and PsA compared with normal, and
glypican-4 labelling was more intense inthe lininglayer ofRA and
PsA compared with normal. These results suggest that there is an
upregulation of selected HSPGs in the chronically inflamed
synovium.
The major difference in HSPG expression between the
synovial samples appeared related to the degree of histological
inflammation (tables 1 and 2). Inflammation, as characterised
by the thickening of the synovial lining layer and infiltration of
the sublining by leukocytes, was absent in normal synovia and
increased in OA, RA and PsA. Similarly the level of HSPG
expression was lowest in normal synovia and increased in OA,
followed by RA and PsA. There was no obvious difference
between the different types of chronic inflammation in terms of
their HSPG expression, since RA and PsA showed an identical
pattern. Therefore the difference in the pathologies of these two
diseases, such as the respective presence or absence of
rheumatoid factor (table 1), did not relate the presence or
absence of particular syndecans or glypicans.
Figure 4 Glypican-4 expression in synovia. A. Staining occurs in the
lining layer and the blood vessels in early rheumatoid arthritis (RA)
synovium. B. The presence of glypican-4 in the lining layer in
longstanding RA. In normal synovium (C), staining occurs in the walls of
blood vessels. Original magnifications A and C 6100, B 650.
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presenting chemokines to chemokine receptors.
13 05 8In addition,
HSPGs act as adhesion molecules, playing an important role in
cell–matrix and cell–cell interactions.
42 9These functions are due
to interactions with the heparan sulphate chains but may also
include the core protein.
29 42 The role of the core protein of
HSPGs is becoming increasingly apparent, not only determining
when and where the heparan sulphate chains are expressed but
also playing a direct role in signalling.
59 Cell–matrix interactions
have been shown for syndecan-3 and syndecan-1 that interact
with extracellular molecules such as collagen and fibronectin.
4
The presence of syndecan-3 on macrophages and syndecan-1 on
Figure 5 Immunohistochemistry for
syndecan-4, glypican-1 and glypican-3 in
synovia and skin. Lack of syndecan-4 (A),
glypican-1 (C) and glypican-3 (E) staining
in rheumatoid arthritis (RA) synovia.
However, staining for syndecan-4 (B) and
glypican-1 (D) does occur in
keratinocytes throughout the epidermis
and glypican-3 is present in the basal cell
layer of the epidermis. Original
magnifications: A and B 6150, C and F
6350, D and E 660.
Extended report
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leukocyte–matrix interactions leading to the accumulation of
these cells in the inflamed synovial tissue. Furthermore, the
presence of syndecan-2 and syndecan-3 on synovial endothelial
cells could be involved in angiogenesis, chemokine presentation
and leukocyte extravasation. With respect to angiogenesis, it is
interesting that growth factors that are thought to drive this
process in the RA synovium require binding to HSPGs for their
activity, underlining an important potential role for HSPGs in
this mechanism.
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